Abstract
The effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) therapy for patients with coronary artery disease has been extensively evaluated [1–5]. According to current guidelines for secondary prevention, an adequate statin therapy is that which lowers low-density lipoprotein cholesterol (LDL-C) to <100mg/dL, or <70mg/dL in the case of very high-risk patients [6]. However, elderly acute myocardial infarction (AMI) patients, a high-risk population themselves, often do not receive the dose of statins recommended by current guidelines because of poor general condition and comorbidities [7].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
